What is Avedian?
Founded in 2017 by the Tabares brothers, Avedian operates at the intersection of artificial intelligence and healthcare administration. The company provides a robust suite of platforms, specifically Hosdatia for clinical environments and Insuria for insurance providers. These tools are engineered to synthesize fragmented, unstructured data into actionable intelligence, facilitating improved medical auditing, billing efficiency, and predictive care coordination. With a client roster that includes major regional entities like Apross and RIMAC Seguros, Avedian has established itself as a critical partner for organizations seeking to optimize their operational performance through data-driven insights. The company's focus on centralizing complex datasets addresses a fundamental pain point in the healthcare industry, enabling stakeholders to transition from reactive management to proactive, predictive decision-making.
How much funding has Avedian raised?
Avedian has raised a total of $2.2M across 1 funding round:
Unspecified
$2.2M
Unspecified (2025): $2.2M with participation from Meet.Capital
Key Investors in Avedian
Meet.Capital
Meet.Capital is a specialized platform that facilitates capital acquisition for startups by connecting founders with a curated network of angel and venture capital investors, providing essential fundraising tools and expert consulting.
What's next for Avedian?
With this major enterprise-level funding, Avedian is poised to enter a new phase of scaling and product refinement. The strategic allocation of this capital will likely focus on expanding the predictive capabilities of its AI models and deepening its market penetration within the insurance and hospital sectors. As the company continues to bridge the gap between clinical data and financial performance, it is well-positioned to capitalize on the growing demand for digital health transformation. Future growth trajectories will likely involve enhancing the interoperability of its platforms and potentially exploring new regional markets, ensuring that Avedian remains at the forefront of the health-tech innovation cycle.
See full Avedian company page
